Filing Flows › UroGen Pharma (URGN) › Q1 2025
UroGen Pharma (URGN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
UroGen Pharma (URGN) reported revenue of $20.3M for the first quarter 2025 (Q1 2025), +8% from a year earlier and -18% from the quarter before. Operating margin was -182.3%, net loss $43.8M (216.5% of revenue).
UroGen Pharma, Q1 2025: revenue $20.3M (+8% year over year), operating margin -182.3%, net loss $43.8M, operating cash flow −$42.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.3M | -18% | +8% |
| Operating profit | −$36.9M | — | — |
| Net earnings | −$43.8M | — | — |
| Operating cash flow | −$42.0M | — | — |
What changed
Revenue was $20.3M in Q1 2025, up 8% year over year and down 18% from the previous quarter.
Gross margin was 88.5%, down 2.3 points from a year earlier. Operating costs exceeded revenue by $36.9M, an operating margin of -182.3%. Operating expenses grew 28% against revenue growth of 8%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $43.8M, wider than the previous quarter's $37.5M loss.
Operating cash flow was −$42.0M. Non-cash charges added back $72K of depreciation and amortization and $3.1M of share-based compensation. Capital expenditures of $44K exceeded it, leaving free cash flow of −$42.1M.
Questions
What was UroGen Pharma's revenue in the first quarter 2025?
UroGen Pharma (URGN) reported revenue of $20.3M for the first quarter 2025 (Q1 2025), +8% from a year earlier and -18% from the quarter before.
Was UroGen Pharma profitable in the first quarter 2025?
Operating loss was $36.9M (-182.3% of revenue) and net loss $43.8M.
Source: UroGen Pharma 10-Q on SEC EDGAR.